Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis

Fig. 1

Didymin suppresses high-fat-induced hepatocellular lipid deposition both in vitro and in vivo. A Chemical structure of Didymin. B Cell viability of AML12 cells treated with PA and different concentrations of Didymin (n = 4). C TG contents in AML12 cells (n = 4). D Lipid accumulation in AML12 cells was visualized using oil red O staining (Scale bar = 20 μm). E A group of MAFLD mice fed with a high-fat diet for 20 weeks and a control group fed with a normal diet were randomly divided into two groups each. After three weeks of Didymin treatment, the lipid deposition in the livers of the four groups of mice was visualized using oil red O staining. Data are expressed as mean ± SD. **P < 0.01, ***P < 0.001, ****P < 0.0001 PA vs. PA + Didymin. ##P < 0.01, ####P < 0.0001 control vs. PA. PA palmitic acid, TG triglyceride

Back to article page